Clinical trials: Neoplasm Circulating Cells
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Neoplasms, Head Cancer
- Trial name
- NCT05420948
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Breast Cancer Females, Circulating Tumor Cells.Breast
Does Anesthesia Technique Impact on the Long-term Outcome 5 and 10 Years After the First Intervention in Primary Breast Cancer Surgery? A Follow-up Analysis.
Goal of this observational study is to analyze data about cancer recurrence rates 5 and 10 years after primary breast cancer surgery with propofol or sevoflurane anesthesia.
- Conditions
- Breast Cancer Females, Circulating Tumor Cells.Breast, Follow Up Analysis
- Trial name
- CTC follow up (NCT07689253)
- Where
- Switzerland
- Volunteers
- 161 people
- Sponsor
- University of Zurich
Non Small Cell Lung Cancer
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer
To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the study of QL1101 and Avastin® in patients with Non-squamous Non-small Cell Lung Cancer
- Trial name
- NCT03195569
- Testing
- QL1101, Avastin®, Paclitaxel
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment
Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive…
- Conditions
- Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment, Radiotherapy, Adaptive Treatment
- Trial name
- PRIMO (NCT05524012)
- Testing
- Blood sample, MRI scan
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Jena University Hospital
Ethmoid Sinus Tumor, Adenocarcinoma
Liquid Biopsy for the Diagnosis of Intestinal-type Adenocarcinoma of the Ethmoid (BLADE)
The role of this transversal study is to assess the specificity and sensitivity of liquid biopsy to detect circulating cells tumor of adenocarcinoma of the ethmoid.
- Conditions
- Ethmoid Sinus Tumor, Adenocarcinoma, Circulating Tumor Cell
- Trial name
- BLADE (NCT06090214)
- Testing
- Liquid biopsy
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Melanoma
Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma
Despite recent advances in cancer treatment, little impact has been made on curing as opposed to controlling cancers over the last several decades.
- Trial name
- NCT02251314
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer, Melanoma
BESPOKE Study of ctDNA Guided Immunotherapy
This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA™ testing.
- Conditions
- Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer
- Trial name
- NCT04761783
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Natera, Inc.
Melanoma
Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy
The goal of this clinical trial is to investigate adaptive therapy in late-stage cutaneous melanoma. The main question it aims to answer are: If the patient having breaks in their treatment allows the less resistant cells to…
- Trial name
- DyNAMIc (NCT06470880)
- Testing
- Adaptive Therapy, Standard of Care
- Volunteers
- 40 people
- Sponsor
- The Christie NHS Foundation Trust
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Cancer
Clinical Validation of a Microfluidic Device for Isolation and Molecular Characterization of Circulating Tumor Cells
To evaluate the efficiency of a microdevice for circulating tumor cells isolation and to correlate the circulating titre with response and progression.
- Trial name
- CTC (NCT01022723)
- Where
- Singapore
- Volunteers
- 817 people
- Sponsor
- National Cancer Centre, Singapore
Metastatic Cancer, Breast Cancer
Biomarkers to Detect Endocrine Therapy Resistance
This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy.
- Conditions
- Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
- Trial name
- NCT06067503
- Testing
- 18F-fluorofuranylnorprogesterone, Liquid Biopsy, Positron Emission Tomography/Computed Tomography
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA
CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.
- Trial name
- GALIA (NCT07418125)
- Testing
- Liquid biopsy
- Where
- Slovenia
- Volunteers
- 130 people
- Sponsor
- Institute of Oncology Ljubljana
Metastatic Non-small Cell Lung Cancer
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
In patients with locally advanced or metastatic tumors, first-line therapeutic management is based on the use of targeted therapies (EGFR, BRAF ALK and ROS1 inhibitors), immunotherapies (anti-PD1/ anti-PDL1-antibodies or…
- Trial name
- ELUCID (NCT03926260)
- Testing
- ctDNA analysis
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Metastatic Breast Cancer
Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)
Prospective multicenter observational study to assess molecular drivers of metastatic breast cancer and disease evolution upon therapeutic pressure.
- Trial name
- NCT03758976
- Testing
- Biopsies, blood
- Where
- 2 sites in Sweden
- Volunteers
- 2,000 people
- Sponsor
- Lund University Hospital
Cancer of Pancreas
Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level
The aim of this work is to evaluate the impact of endoscopic procedures on the circulating tumoral cells level in order to evaluate the potential effects of an endoscopic procedure in the management of pancreatic tumors.
- Trial name
- EUS-CTC (NCT04677244)
- Testing
- Blood sample in portal vein
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Institut Paoli-Calmettes
Advanced NSCLC, Circulating Tumor Cells
Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Verify the Coincidence rate between Circulating tumor cells (CTCs) and tumor tissue or Circulating tumor DNA (ctDNA) of advanced NSCLC patients with Driver gene mutation
- Conditions
- Advanced NSCLC, Circulating Tumor Cells, Circulating Tumor DNA
- Trial name
- NCT04229121
- Testing
- nonintervention
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Colorectal Cancer Metastatic
Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)
The purpose of the study is to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab, as first line therapy of patients with RAS wild-type metastatic colorectal carcinoma and < 3…
- Trial name
- VISNU-2 (NCT01640444)
- Testing
- FOLFIRI + bevacizumab, FOLFIRI + cetuximab
- Where
- Spain
- Volunteers
- 240 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Carcinoma, Hepatocellular, Neuroendocrine Tumors
Circulating Tumor Cells and Tumor DNA in HCC and NET
Background Treatment and control of cancer is associated with high costs, to patients in the form of side effects and discomfort during investigations, to society in the form of expensive drugs and studies.
- Trial name
- NCT02973204
- Testing
- Sorafenib, Radiofrequency ablation (RFA) or surgery, Everolimus
- Where
- Denmark
- Volunteers
- 167 people
- Sponsor
- University of Aarhus
Head and Neck Cancer
Detection in Peripheral Blood of Circulating Tumor Cells in Patient With Head and Neck Squamous Cell Carcinoma
The dissemination of individual tumor cells is a common phenomenon in solid cancers. Detection of tumor cells in peripheral blood circulating tumor cells (CTC) in nonmetastatic situation is of high prognostic significance.
- Trial name
- CTCVADS (NCT02892786)
- Testing
- Circulating Tumor Cells
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Institut de Cancérologie de Lorraine
Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
This is a randomized phase II trial for patients with HER2 negative primary Breast Cancer (BC) who after completing (neo) adjuvant chemotherapy and surgery have detectable circulating tumour cells (CTC) in peripheral blood.
- Conditions
- Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Circulating Tumor Cells
- Trial name
- TREAT-CTC (NCT01548677)
- Testing
- trastuzumab
- Where
- 80 sites in Belgium, France and 2 more
- Volunteers
- 1,317 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC